Astellas Pharma Inc (ALPMY)

9.53 +0.03 (+0.32%)
Close USD Disclaimer
9.52 -0.01 (-0.10%)

Astellas Pharma Inc Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
14484
Equity Type
ADR
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Contact Information
Address
Tokyo,103-8411 Japan
Phone
81 3 3244 3000
Fax
-
Top Executives
Name
Age
Since
Title
Kenji Yasukawa 63 2017 Chairman of the Board
Rie Akiyama 53 2023 Outside Independent Director
Eriko Sakurai 63 2022 Independent Outside Director
Mika Nakayama 0 2022 Independent Outside Director
Yoichi Ohno 62 2023 Outside Independent Director
Raita Takahashi 61 2020 Independent Outside Director
Takashi Tanaka 66 2021 Independent Outside Director
Katsuyoshi Sugita 56 2021 Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles